Psilocybin-related businesses are companies that operate in the growing commercial ecosystem around psilocybin, the psychoactive compound found in certain mushrooms. These range from pharmaceutical companies running clinical trials to service centers where people legally consume psilocybin under supervision, along with dozens of supporting businesses in between. The broader psychedelic drugs market was valued at roughly $1.92 billion in 2024 and is projected to reach $3.8 billion by 2030, growing at about 12% per year.
The Six Main Business Categories
The psilocybin business landscape breaks down into six broad areas: drug discovery and development, novel formulations, manufacturing and synthesis, treatment centers and wellness clinics, consumer packaged goods, and supporting technology companies. Of these, drug development commands the most activity. Most companies in the space are working on creating new psilocybin-based medications or finding better ways to deliver the compound, such as faster-acting formulations or versions with shorter trip durations.
Venture capital has been the primary funding engine, with most investment dollars flowing into early-stage biotech companies during their first major fundraising rounds. This heavy tilt toward pharmaceutical development reflects where the biggest potential payoff lies: FDA-approved psilocybin therapies that could be prescribed by psychiatrists nationwide.
Pharmaceutical and Biotech Companies
The highest-profile psilocybin businesses are biotech firms developing prescription medications. These companies are running clinical trials aimed at proving psilocybin works for conditions like major depressive disorder and treatment-resistant depression. The Usona Institute, for example, is conducting a Phase 3 trial testing a single 25 mg oral dose of psilocybin against placebo in 240 adults with major depressive disorder, with results expected by late 2026.
Some companies are developing modified versions of the psilocybin molecule rather than using the natural compound. Cybin Inc. created a proprietary psilocybin analog that received FDA Breakthrough Therapy Designation for major depressive disorder. That designation is significant because it fast-tracks the review process, signaling the FDA believes the treatment may offer a substantial improvement over existing options. These modified compounds aim to deliver the therapeutic benefits of psilocybin while addressing limitations like the length of a session (which can run six hours or more with natural psilocybin).
Licensed Service Centers
Oregon became the first U.S. state to create a legal, regulated framework for psilocybin use outside of clinical trials. Under this model, licensed service centers are the only locations where clients can legally purchase and consume psilocybin. This is not a dispensary model. You cannot buy psilocybin and take it home. Instead, you must first complete a preparation session with a licensed facilitator, then consume the psilocybin on-site under supervision.
Service center operators can design different types of experiences, including individual sessions, group sessions, or outdoor administration. Colorado has followed with its own regulated framework. These service centers represent an entirely new category of licensed business, more comparable to a supervised wellness clinic than a pharmacy or retail shop.
International Retreat Operations
Outside the U.S., psilocybin retreat centers operate in countries where the compound is either legal or exists in a legal gray area. Jamaica is one of the most popular destinations because psilocybin has never been illegal there. Nepal is another jurisdiction where psilocybin is not explicitly covered by drug control laws, making it functionally legal. In Mexico, psychedelics are generally illegal, but an exception in federal law protects spiritual or ceremonial use of psilocybin, which has made the country a hotspot for retreat businesses.
These international retreats typically bundle accommodation, preparation counseling, guided psilocybin sessions, and integration support into multi-day packages. They operate as wellness tourism businesses and draw clients primarily from countries where psilocybin remains illegal.
Training and Education Programs
Regulated psilocybin use requires trained facilitators, which has created a market for accredited training programs. In Oregon, becoming a licensed facilitator requires completing a 150-hour state-approved training program, a 40-hour practicum, and 50 hours of consultation. Universities have moved into this space. Naropa University offers a psilocybin facilitator training certificate program built around mentorship, small group instruction, and hands-on skill building.
As more states consider legalizing supervised psilocybin use, the demand for qualified facilitators is expected to grow, making training programs a steady revenue stream within the industry.
Technology and Software Platforms
A layer of specialized technology companies has emerged to serve psilocybin and psychedelic therapy practices. These businesses build electronic health record systems, clinic management software, and patient communication tools tailored to the unique workflows of psychedelic-assisted therapy. Standard medical software wasn’t designed for sessions that last several hours, require detailed vitals monitoring, or involve specific regulatory compliance steps.
Platforms in this space offer features like customizable clinical notes, automated insurance authorization, HIPAA-compliant patient messaging, and outcome tracking tools that turn subjective therapy results into measurable data. Some also integrate compliance workflows required by federal risk management programs, which will be essential if psilocybin therapies receive FDA approval.
Insurance and Legal Services
Ancillary service businesses are filling the gaps around the core psilocybin industry. On the insurance side, some private payers are already covering psychedelic therapy. Enthea, a third-party administrator, offers psychedelic therapy coverage as an add-on benefit similar to dental or vision insurance. They handle the reimbursement process for providers, employers, and insurers, reducing the administrative burden on clinics.
Specialized legal firms have also become a significant part of the ecosystem. Psilocybin businesses face a patchwork of state and federal regulations, and companies need attorneys who understand both drug scheduling law and the emerging state-level licensing frameworks. Laboratory testing services round out the ancillary market, providing quality assurance and potency testing for psilocybin products used in both clinical and supervised settings.
Existing Clinics Expanding Into Psilocybin
Some businesses already operating in adjacent spaces are positioning themselves to add psilocybin services once regulations allow it. Companies like Field Trip Health & Wellness and Awakn currently offer ketamine-assisted psychotherapy and have built out the physical infrastructure, clinical protocols, and trained staff needed to administer psychedelic-assisted therapies. When psilocybin treatments receive broader approval, these clinics can expand their offerings without starting from scratch. This hybrid model reduces risk for operators by generating revenue from already-legal treatments while staying ready for the next wave of approvals.